Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-modified immune cell therapy. The company was founded in 2017 and is based in Taipei, Taiwan.